

BioPharma

Latest Updates

Here are this week's BioPharma updates - **September 8th, 2025.**

Funding

- [Treeline Biosciences](#) (MA, USA) raised a \$200M Series A extension funding, bringing total funding to \$1.1B, to advance its pipeline including new Phase 1 trials of a BCL6 degrader, pan-KRAS inhibitor, and EZH2 inhibitor for cancer.
- [Enveda](#) (CO, USA) raised \$150M in Series D funding to expand its platform and advance a pipeline of small-molecule drugs for atopic dermatitis, asthma, inflammatory bowel disease, and obesity.
- [Galvanize Therapeutics](#) (CA, USA) raised \$100M in an oversubscribed Series C funding to expand commercialization and advance its pulsed electric field therapies for solid tumors and chronic bronchitis.
- [ViCentra](#) (Utrecht, Netherlands) raised \$85M in Series D funding to scale manufacturing and support commercialization of Kaleido 2, its next-generation lifestyle-oriented insulin patch pump, in Europe and the U.S.
- [CHARM Therapeutics](#) (London, United Kingdom) raised \$80M in Series B funding to advance its AI-designed menin inhibitor into clinical trials for acute myeloid leukemia.
- [Ronovo Surgical](#) (Shanghai, China) raised \$67M in Series D funding to accelerate commercialization of its Carina™ modular robotic surgery platform in China and support international expansion.
- [MRM Health](#) (Ghent, Belgium) raised \$64M in Series B funding to advance its Phase 2b trial of MH002 for ulcerative colitis, progress additional microbiome-based programs to IND stage, and expand its CORAL® platform.
- [Mercy BioAnalytics](#) (MA, USA) raised \$59M in Series B funding to advance the commercialization of its extracellular vesicle-based ovarian cancer blood tests and expand its early cancer detection portfolio.

- [Rapafusyn Pharmaceuticals](#) (MD, USA) raised \$44M in Series A funding to advance its RapaGlue™ non-degrading molecular glue platform and progress its pipeline - including an ENT1 inhibitor - toward IND-enabling studies.
- [Octave Bioscience](#) (CA, USA) raised \$35.6M in Series C funding to expand commercialization of its MSDA test for multiple sclerosis and advance its precision neurology pipeline, including programs in Parkinson's disease.
- [Congruence Therapeutics](#) (Montreal, Canada) raised \$32M in funding to advance its lead genetic obesity candidate CGX-926 through Phase 1b proof-of-concept trials and progress additional programs in Parkinson's disease and Alpha-1 antitrypsin deficiency.
- [LPOXY Therapeutics](#) (MO, USA) secured a \$28M Series A funding commitment to launch its registrational STOP-Cdiff trial of SIDIPREV™, a novel non-antibiotic therapy to prevent Clostridioides difficile infections in high-risk patients.
- [Boomerang Medical](#) (CA, USA) raised \$20M in Series B funding to advance a pivotal trial evaluating implantable neuromodulation for ulcerative colitis in inflammatory bowel disease.
- [Revalia Bio](#) (CT, USA) raised \$14.5M in seed funding to launch its Human Data Trials platform, which uses perfused human organs to generate predictive insights for drug development and improve translation to clinical outcomes.
- [Nutromics](#) (Melbourne, Australia) raised \$5M in funding to advance its "lab-on-a-patch" wearable diagnostics platform, initially targeting vancomycin monitoring and future ICU applications.
- [Berlin Heals](#) (Zug, Switzerland) raised over \$5M in funding to advance development of its less invasive cardiac microcurrent implant procedure for treating heart failure.
- [Sunflower Therapeutics](#) (MA, USA) received a \$2.36M NIH SBIR grant, with \$300K awarded initially, to develop an automated continuous cell disruption platform to improve large-scale VLP vaccine manufacturing.
- [Rivanna](#) (VA, USA) received a \$2.21M NIH SBIR Phase II grant to develop pediatric lumbar puncture ultrasound guidance features on its Accuro 3S platform.
- [Monod Bio](#) (WA, USA) received a \$1.5M Gates Foundation grant to develop a urine-based rapid diagnostic test for tuberculosis using its de novo protein design NovoBody™ technology.

- [Lucia Bio](#) (Brisbane, Australia) raised an additional \$1.3M in Seed funding, bringing its total Seed round to \$2M, to advance development of its selective Syk inhibitors for neuroinflammatory and autoimmune diseases, including progression of lead asset QED-701 into toxicology studies and QED-121 into CMC activities.
- [Zeteo Tech](#) (MA, USA) received a \$1M CARB-X grant to advance its BreathBiomics™ diagnostic platform, which uses exhaled breath to rapidly detect and characterize lower respiratory tract infections in critical care patients.
- [Neucore Bio](#) (OH, USA) received a \$350K NIH STTR Phase I grant to develop its engineered exosome platform for delivering RNA-based therapies to treat Charcot-Marie-Tooth Disease Type 1A.
- [LambdaVision](#) (CT, USA) received a NASA Phase 2 InSPA grant to advance manufacturing of its protein-based artificial retina in low-Earth orbit, supporting process scale-up and quality improvements ahead of IND-enabling studies.

Emerging

- [Corsera Health](#) (MA, USA) emerged from stealth with \$50M in seed funding to develop a once-annual RNAi therapy for heart disease prevention alongside an AI-driven cardiovascular risk prediction tool.
- [Shenandoah Therapeutics](#) (CA, USA) raised \$21.5 M in seed funding to advance its innovative transcriptional chemical inducer of proximity (TCIP) platform—designed to rewire cancer-driving proteins (like BCL6) into triggers of self-destruction in tumor cells.
- [OpZira](#) (PA, USA) launched to advance ophthalmic diagnostics with a portfolio of medical devices, including the AdaptDx Pro dark adaptometer and the NOVA Vision Testing System, to improve early detection and monitoring of ocular disease.

Post IPO Equity

- [Bruker](#) (MA, USA) announced a public offering of \$600M in Mandatory Convertible Preferred Stock to repay outstanding debt, strengthen its balance sheet, and enhance strategic flexibility.

- [Mineralys Therapeutics](#) (PA, USA) announced pricing of an upsized underwritten public offering to raise \$250M to fund clinical development of lorundrostat, research and manufacturing, pre-commercialization activities, and general corporate purposes.
- [vTv Therapeutics](#) (NC, USA) raised \$80M in a PIPE financing to fund its ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes.
- [Aethlon Medical](#) (CA, USA) announced pricing of a public offering to raise \$4.5M through common stock, pre-funded warrants, and accompanying warrants, with proceeds intended for clinical trials, R&D, working capital, and general corporate purposes.
- [Artelo Biosciences, Inc.](#) (CA, USA) announced pricing of an underwritten public offering to raise \$3M through common stock and pre-funded warrants, with proceeds intended to advance its pipeline of lipid-signaling pathway therapies, dermatologic, and neurological conditions.
- [PreveCeutical Medical Inc.](#) (West Vancouver, Canada) raised \$646.5K in an initial tranche of a planned \$1M non-brokered private placement to pay outstanding payables, operating expenses, and for general working capital purposes.
- [NeuroSense Therapeutics](#) (MA, USA) raised \$500K in a private placement of ordinary shares at a 40% premium to market price to support working capital and general corporate purposes.

Post IPO Debt

- [Precigen](#) (MD, USA) secured a \$100M first tranche from a \$125M credit facility with Pharmakon Advisors to fortify its balance sheet, support US commercialization of PAPZIMEOS, and enable potential international expansion and pursuit of pediatric and other HPV-related indications.
- [Mesoblast](#) (Melbourne, Australia) entered into agreements to issue up to \$50M in unsecured convertible notes at its discretion to repay secured lenders and support general working capital and pipeline growth opportunities.

Mergers and Acquisitions

- [University of Texas at San Antonio](#) (TX, USA) to acquire [UT Health San Antonio](#) (TX, USA) to strengthen education, research, and healthcare through academic integration.
- [CapVest](#) (London, United Kingdom) to acquire [Stada](#) (Bad Vilbel, Germany) to cancel prior IPO plans and strengthen its generics and specialty pharma portfolio.
- [CorMedix](#) (NJ, USA) to acquire [Melinta Therapeutics](#) (NJ, USA) to expand its anti-infectives portfolio and strengthen financial guidance with a new leadership team.
- [SeqOne](#) (Montpellier, France) to acquire [Congenica](#) (Cambridge, United Kingdom) to create a global leader in AI-powered genomic medicine.
- [Johnson & Johnson](#) (NJ, USA) to acquire [OBaris](#) (Zurich, Switzerland), formerly known as Transire Bio, to strengthen its surgical oncology portfolio and expand minimally invasive cancer treatment options.

Partnerships

- [Argo Biopharma](#) (Shanghai, China) and [Novartis](#) (Basel, Switzerland) announced a ~\$5.36B strategic collaboration granting Novartis rights to multiple cardiovascular siRNA assets, including an option on Argo's Phase 2 ANGPTL3 program and licenses to additional pipeline candidates.
- [Arrowhead Pharmaceuticals](#) (CA, USA) and [Novartis](#) (Basel, Switzerland) announced a ~\$2.2B global licensing and collaboration agreement granting Novartis exclusive worldwide rights to ARO-SNCA, Arrowhead's preclinical siRNA therapy for synucleinopathies including Parkinson's Disease.
- [Enlaza Therapeutics](#) (CA, USA) and [Vertex Pharmaceuticals](#) (MA, USA) announced a ~\$2.05B multi-target drug discovery collaboration to develop covalent biologics using Enlaza's War-Lock platform for autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.
- [Radiance Biopharma](#) (MA, USA) and [Novatim Immune Therapeutics](#) (Shanghai, China) announced a ~\$1.2B exclusive license agreement for RB-601™, a first-in-class bispecific nanobody ADC targeting c-MET and EGFR for the treatment of solid tumors.
- [Hengrui Pharma Co., Ltd](#) (Shanghai, China) and Braveheart Bio (CA, USA) announced a ~\$1.01B exclusive licensing agreement granting Braveheart Bio worldwide rights (ex-China) to develop and commercialize HRS-1893, a Phase 3 therapy for obstructive hypertrophic cardiomyopathy.

- [Servier](#) (Suresnes, France) and [IDEAYA Biosciences](#) (CA, USA) announced a ~\$530M exclusive license agreement to advance and commercialize darovasertib for uveal melanoma outside the United States.
- [OMass Therapeutics](#) (Oxford, United Kingdom) and [Genentech](#) (CA, USA) announced a ~\$420M exclusive collaboration and license agreement to advance its preclinical oral small molecule program for inflammatory bowel disease.
- [Zenas BioPharma](#) (MA, USA) and [Royalty Pharma](#) (NY, USA) announced a royalty-based funding agreement worth up to \$300M to support late-stage development and commercialization of obexelimab for IgG4-Related Disease and other autoimmune indications.
- Avadel Pharmaceuticals PLC (Dublin, Ireland) and [XWPharma](#) (CA, USA) announced a ~\$215M exclusive global license agreement for valiloxbate, a once-at-bedtime, salt-free oxybate therapy for narcolepsy and idiopathic hypersomnia.
- [Rallybio](#) (CT, USA) received a \$12.5M equity milestone payment from [Recursion](#) (UT, USA) triggered by additional preclinical studies of REV102, an oral ENPP1 inhibitor for hypophosphatasia, extending Rallybio's cash runway through 2027.
- Cardiac Biotech Solutions, Inc. (NV, USA) and Noventis Medical (Escazu, Costa Rica) announced a \$600K five-year exclusive distribution agreement for CBSC's MyCardia AT cardiac monitoring products in Costa Rica, Panama, Colombia, and Argentina.
- [Lotte Biologics](#) (Seoul, South Korea) announced a late-stage commercial contract manufacturing partnership with a U.S.-based global biopharma company to support a Phase 3 program, potential commercial supply, and expanded access to innovative therapies through 2030.
- [LenioBio](#) (Düsseldorf, Germany) and [AffinityAI](#) (Kongens Lyngby, Denmark) announced a strategic partnership to integrate cell-free protein expression with AI-driven protein design to accelerate the discovery and optimization of de novo proteins for next-generation therapeutics.
- [Polpharma Biologics](#) (Gdańsk, Poland) and [MS Pharma](#) (Amman, Jordan) announced licensing agreements for the commercialization of three biosimilar candidates (vedolizumab, ocrelizumab, and guselkumab) across the MENA region, including local fill and finish operations in Saudi Arabia.
- [Medipal Holdings Corporation](#) (Tokyo, Japan) and [JCR Pharmaceuticals](#) (Ashiya, Japan) announced an exclusive global licensing deal and Japan co-development and commercialization partnership for JR-479, an investigational therapy for GM2 gangliosidosis.

- [Vyriad](#) (MN, USA) and [Weizmann Institute of Science](#) (Israel) announced an exclusive license agreement for a novel viral vector targeting technology from the Weizmann Institute, aiming to enhance in vivo genetic therapies by improving specificity while preserving potency.
- [Biotia](#) (NY, USA) and [Hospital for Special Surgery](#) (NY, USA) announced a collaboration to advance diagnostics for prosthetic joint infection by combining Biotia's AI and sequencing platform with HSS's clinical expertise to improve early detection and patient outcomes.
- [Twist Bioscience](#) (CA, USA) and [Synthetic Design Lab](#) (CA, USA) announced a collaboration to leverage Twist's high-throughput antibody discovery and screening services to advance SDL's SYNTHBODY platform and develop novel antibody-drug conjugates for cancer.
- [Naobios](#) (Saint-Herblain, France), [Nuvonis Technologies GmbH](#) (Vienna, Austria), and [European Vaccine Initiative \(EVI\)](#) (Heidelberg, Germany) announced a collaboration through the Inno4Vac consortium to develop an influenza A(H3N2) Human Viral Challenge Agent leveraging Nuvonis' GMP Vero Cell Bank for controlled human infection model studies.
- [BioLab Holdings](#) (AZ, USA) and [cureVision](#) (Germany) announced a strategic investment and commercialization partnership to bring cureVision's AI-driven wound assessment technology to the U.S. market, supporting regulatory, reimbursement, and nationwide distribution efforts.
- [Biocytogen](#) (Beijing, China) and [Merck](#) (NJ, USA) announced an evaluation and option agreement to develop antibody-conjugated lipid nanoparticle delivery systems for nucleic acid payloads, with Merck gaining exclusive rights to selected antibody assets in exchange for fees and royalties.
- [Regenerex Pharma, Inc.](#) (NV, USA) and [Holista Colltech](#) (Sydney, Australia) announced a binding supply and development agreement granting Regenerex exclusive worldwide rights to Holista's ovine collagen technologies for advanced wound care products, with initial commercialization in the U.S. and global expansion to follow.
- [Stallergenes Greer](#) (Baar, Switzerland) and [Nuance Pharma](#) (Shanghai, China) announced an exclusive long-term partnership to develop and commercialize Actair®, a sublingual allergen immunotherapy tablet for house dust mite-induced allergic rhinitis, in the Chinese market.
- [Idorsia Pharmaceuticals Ltd](#) (Allschwil, Switzerland), [Stanford Hypertension Center, Stanford University School of Medicine](#) (CA, USA), and [Duke Heart Center](#) (NC, USA) announced a multi-phase collaboration to launch IMPACT-HTN, a program to standardize treatment, generate real-world evidence, and apply AI-powered tools to improve outcomes for patients with difficult-to-control hypertension.

- [BrainSpec](#) (MA, USA) and the [University of Minnesota Center for Magnetic Resonance Research](#) (MN, USA) announced an exclusive license agreement to commercialize AutoVOI, an automated pipeline that streamlines voxel placement in MR spectroscopy to improve precision, reproducibility, and accessibility.
- [Zydus Group](#) (India) and [Synthon](#) (Nijmegen, Netherlands) announced an exclusive licensing and supply agreement for generic Ozanimod Capsules (ZEPOSIA®) in the U.S. market, with Synthon handling regulatory approval and manufacturing and Zydus leading commercialization.
- [Predictive Oncology](#) (PA, USA) and [Every Cure](#) (PA, USA) announced a strategic collaboration to leverage AI-driven platforms and tumor sample data to accelerate drug repurposing and expand treatment options for patients with unmet medical needs.

Registered Direct Offering

- [STRATA Skin Sciences](#) (PA, USA) announced pricing of a \$2.42M registered direct offering to support working capital and general corporate purposes.

Closures and Layoffs

- [Novartis](#) (Basel, Switzerland) to lay off 58 employees in NJ, USA for operational review at its U.S. headquarters.
- [AC Immune](#) (Lausanne, Switzerland) to lay off 30% of employees to preserve cash and streamline its pipeline.